Merck KGaA Gestion

Gestion contrôle des critères 4/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Belen Garijo Lopez

Directeur général

€10.5m

Rémunération totale

Pourcentage du salaire du PDG	14.2%
Durée du mandat du directeur général	9.8yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	6.1yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Belen Garijo Lopez a-t-elle évolué par rapport aux bénéfices de Merck KGaA?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	€3b
Jun 30 2024	n/a	n/a	€3b
Mar 31 2024	n/a	n/a	€3b
Dec 31 2023	€11m	€2m	€3b
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€3b
Mar 31 2023	n/a	n/a	€3b
Dec 31 2022	€11m	€2m	€3b
Sep 30 2022	n/a	n/a	€3b
Jun 30 2022	n/a	n/a	€3b
Mar 31 2022	n/a	n/a	€3b
Dec 31 2021	€9m	€1m	€3b
Sep 30 2021	n/a	n/a	€3b
Jun 30 2021	n/a	n/a	€3b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	€7m	€1m	€2b
Sep 30 2020	n/a	n/a	€2b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	€6m	€1m	€1b
Sep 30 2019	n/a	n/a	€1b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€938m
Dec 31 2018	€7m	€1m	€1b
Sep 30 2018	n/a	n/a	€2b
Jun 30 2018	n/a	n/a	€2b
Mar 31 2018	n/a	n/a	€2b
Dec 31 2017	€6m	€1m	€3b

Rémunération vs marché: La rémunération totale de Belen ($USD 11.08M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 12.74M ).

Rémunération et revenus: La rémunération de Belen a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Belen Garijo Lopez (64 yo)

9.8yrs

Titularisation

€10,527,000

Compensation

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Belen Garijo Lopez	Chair of Executive Board & CEO	9.8yrs	€10.53m	pas de données
Helene von Roeder	CFO & Member of Executive Board	1.3yrs	€1.23m	pas de données
Kai Beckmann	CEO of Electronics & Member of the Executive Board	13.6yrs	€8.26m	pas de données
Peter Guenter	CEO of Healthcare Business & Member of Executive Board	3.8yrs	€5.58m	pas de données
Matthias Heinzel	CEO of Life Science Sector & Member of Executive Board	3.6yrs	€5.22m	pas de données
Barbara Weiland	Chief Compliance Officer	5.3yrs	pas de données	pas de données
Dietmar Eidens	Head of the Global HR Business Partner Organization	9.8yrs	pas de données	pas de données
Frank Gotthardt	Head of Corporate & Government Relations - Europe	15.4yrs	pas de données	pas de données
Marc Horn	Head of Life Science Controlling	no data	pas de données	pas de données
Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	7.6yrs	pas de données	pas de données
Hans-Joachim Neumann	Head of Integrated Supply Chain	6.1yrs	pas de données	pas de données
Tina Sandmann	Head of Internal Auditing	5.3yrs	pas de données	pas de données

6.1yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de MKKG.Y est chevronnée et expérimentée (6.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Dietmar Oeter	Independent Member of Supervisory Board	10.5yrs	€50.80k	pas de données
Alexander Putz	Member of Supervisory Board	4.5yrs	€50.80k	pas de données
Stefan Palzer	Supervisory Board Member	less than a year	pas de données	pas de données
Barbara Lambert	Independent Member of Supervisory Board	1.3yrs	€30.50k	pas de données
Sascha Held	Vice Chair of Supervisory Board	5.6yrs	€89.30k	pas de données
Michael Kleinemeier	Independent Chairman of Supervisory Board	5.6yrs	€50.80k	pas de données
Anne Lange	Independent Member of Supervisory Board	5.6yrs	€50.80k	pas de données
Christian Raabe	Independent Member of Supervisory Board	5.6yrs	€65.80k	pas de données
Daniel Thelen	Independent Member of Supervisory Board	5.6yrs	€65.80k	pas de données
Simon Thelen	Independent Member of Supervisory Board	5.6yrs	€50.80k	pas de données
Birgit Biermann	Member of Supervisory Board	2.3yrs	€50.80k	pas de données
Katja Vila	Supervisory Board Member	less than a year	pas de données	pas de données

5.6yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de MKKG.Y sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).

Merck KGaA Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Merck KGaA Announces Executive Changes

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Merck Launches New, High-Purity Synthetic Cholesterol Product

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2020 Results on Mar 04, 2021

MERCK Kommanditgesellschaft auf Aktien to Discontinue Bintrafusp Alfa Clinical Trial (INTR@PID Lung 037)

Merck KGaA, Darmstadt, Germany to Deploy Insilico Medicine's Chemistry42 AI Platform for Generative Chemistry

Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Iktos Announces Additional Collaboration with Merck KGaA, Darmstadt, Germany in AI for New Drug Design

Merck KGaA Announces Executive Changes

LycoRed Natural Products Industries Ltd. acquired Nutriblend Ltd. from Merck KGaA.

Rakuten Medical Enters into Partnership with Merck

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2021 Results on Aug 05, 2021

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen